↓ Skip to main content

Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs

Overview of attention for article published in Parasites & Vectors, October 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs
Published in
Parasites & Vectors, October 2015
DOI 10.1186/s13071-015-1123-8
Pubmed ID
Authors

Feli M. Walther, Mark J. Allan, Rainer KA Roepke

Abstract

Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose. Ivermectin has been used in dogs for heartworm prevention and at off label doses for mite and worm infestations. Ivermectin pharmacokinetics can be influenced by substances affecting the p-glycoprotein transporter, potentially increasing the risk of ivermectin neurotoxicity. This study investigated ivermectin blood plasma pharmacokinetics following concurrent administration with fluralaner. Ten Beagle dogs each received a single oral administration of either 56 mg fluralaner (Bravecto™), 0.3 mg ivermectin or 56 mg fluralaner plus 0.3 mg ivermectin/kg body weight. Blood plasma samples were collected at multiple post-treatment time points over a 12-week period for fluralaner and ivermectin plasma concentration analysis. Ivermectin blood plasma concentration profile and pharmacokinetic parameters Cmax, tmax, AUC∞ and t½ were similar in dogs administered ivermectin only and in dogs administered ivermectin concurrently with fluralaner, and the same was true for fluralaner pharmacokinetic parameters. Concurrent administration of fluralaner and ivermectin does not alter the pharmacokinetics of either compound. Based on the plasma pharmacokinetic profile and the clinical observations, there is no evident interaction between fluralaner and ivermectin, and co-administration does not increase the risk of ivermectin associated neurotoxicity.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 3%
Australia 1 3%
Unknown 34 94%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 6 17%
Researcher 6 17%
Professor 5 14%
Student > Ph. D. Student 5 14%
Student > Bachelor 4 11%
Other 8 22%
Unknown 2 6%
Readers by discipline Count As %
Veterinary Science and Veterinary Medicine 10 28%
Agricultural and Biological Sciences 9 25%
Medicine and Dentistry 4 11%
Biochemistry, Genetics and Molecular Biology 3 8%
Engineering 2 6%
Other 3 8%
Unknown 5 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2015.
All research outputs
#11,069,880
of 12,451,686 outputs
Outputs from Parasites & Vectors
#2,806
of 3,208 outputs
Outputs of similar age
#225,427
of 273,221 outputs
Outputs of similar age from Parasites & Vectors
#351
of 417 outputs
Altmetric has tracked 12,451,686 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,208 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,221 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 417 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.